Analysts’ Top Picks: Sarepta Therapeutics, Kezar Life Sciences and Regeneron

Three healthcare companies have caught the attention of bullish analysts recently. Sarepta Therapeutics (Nasdaq: SRPT) , Kezar Life Sciences (Nasdaq: KZR), and Regeneron (Nasdaq: REGN), have been identified as top picks.

Gil Blum, an analyst at Needham, has maintained a Buy rating on Sarepta Therapeutics. Blum has set a price target of $185.00 for the company. Mizuho Securities has also maintained a Buy rating on Sarepta, with a price target of $160.00.

Kezar Life Sciences has been identified as a strong investment opportunity by Maury Raycroft, an analyst at Jefferies, who maintains a Buy rating on the company with a price target of $15.00. Despite the company closing near its 52-week low of $2.25, Raycroft remains bullish.

Regeneron has been given a Buy rating by Akash Tewari, an analyst at Jefferies. Tewari has set a price target of $948.00 for the company. Analyst consensus on Regeneron is a Moderate Buy, with an average price target of $882.27.

These bullish healthcare analysts have identified Sarepta Therapeutics, Kezar Life Sciences, and Regeneron as strong investment opportunities in the healthcare sector. With their expertise and research, these analysts have provided valuable insights for investors looking to make informed decisions.